By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


CeloNova BioSciences 

18615 Tuscany Stone
Suite 100
San Antonio   Texas  78258  U.S.A.
Phone: 210-489-4000 Fax: 210-403-2008


Medical Device

Company News
CeloNova BioSciences Release: FDA Approves NanoCoated Coronary Stent System Using DSG, Inc.’s eClinical Systems 3/23/2017 10:49:24 AM
CeloNova BioSciences Release: Medtech Announces Clinical Results From Pivotal Pzf SHIELD Clinical Trial Published In The Journal Of The American College Of Cardiology: Cardiovascular Interventions 1/24/2017 10:48:57 AM
After Scoring a $70 Million Deal With Boston Scientific (BSX), CeloNova BioSciences CEO Heads to Nonprofit 9/20/2016 7:05:23 AM
Boston Scientific (BSX) Buys CeloNova BioSciences' Interventional Radiology Biz for $70 Million+ 11/10/2015 7:01:20 AM
CeloNova BioSciences Announces FDA Approval To Start A Randomized Trial For The COBRA PzF Coronary Stent System 9/21/2015 1:16:39 PM
CeloNova BioSciences Announces Accelerated IDE Trial Enrollment Completion For Its COBRA Pzf Coronary Stent System 2/19/2015 11:02:53 AM
CeloNova BioSciences Receives Expanded Indication For Benign Prostatic Hyperplasia (BPH) 1/14/2015 10:13:09 AM
GRCI 2014 Update: CeloNova BioSciences' COBRA Pzf™ Coronary Stent Achieves A Low 3% TLR With Short DAPT 12/12/2014 8:19:12 AM
CeloNova BioSciences's Super-Selective Embolic Microsphere With Drug Loading Capabilities Could Mean Improved Quality Of Life And Overall Survival For Liver Cancer Patients 10/30/2014 10:35:05 AM
CeloNova BioSciences Release: First-In-Man Study Of The COBRA PzF™ Coronary Stent Shows Promising Results Highlighted By Short, 30-Day Dual-Antiplatelet Therapy And Low, 3% TLR Rate 9/16/2014 8:52:12 AM